Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 136

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 136
---
 studies;                                                  |

| ● | refusal of the FDA to approve pending applications or supplements                    
 to approved applications, or suspension or revocation of existing product approvals; |

| ● | product seizure or detention, or refusal of the FDA to permit 
 the import or export of products; or                          |

| ● | injunctions or the imposition of civil or criminal penalties. |

The FDA closely regulates the marketing, labeling, advertising and promotion of biologic regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s communications on the subject of off-label use of their products. 85 DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE Executive Officers and Directors The following table sets forth information regarding our executive officers and directors, including their ages as of May 21, 2025:

| Name                         |     | Age |     | Position                             |
| BOARD OF DIRECTORS           |     |     |     |                                      |
| George Tidmarsh, M.D., Ph.D. |     |  65 |     | Chairman and Director                |
| James Rolke                  |     |  56 |     | Director and Chief Executive Officer |
| Jennifer Carver, BSN, MBA    |     |  71 |     | Director                             |
| Jess Roper                   |     |  60 |     | Director                             |
| Lakhmir Chawla, M.D.         |     |  54 |     | Director                             |
| EXECUTIVE OFFICERS           |     |     |     |                                      |
| James Rolke                  |     |  56 |     | Director and Chief Executive Officer |
| Chester S. Zygmont, III      |     |  45 |     | Chief Financial Officer              |

Our Director and Executive Officers George Tidmarsh, M.D., Ph.D. — Chairman.Dr. Tidmarsh has been Chairman of the Company since its inception in May 2020. Dr. Tid